Learn more about our Diagnostics work.
Today, AdvaMedDx® submitted comments in response to the Food and Drug Administration’s Proposed Rule: Medical Devices; Laboratory Developed Tests. AdvaMedDx® is a division of AdvaMed® representing companies that develop in…
Today, AdvaMedDx®, a division of AdvaMed® representing manufacturers of innovative in vitro diagnostic tests, sent a letter urging Congressional leaders to prioritize the reauthorization of the President’s Emergency Plan for…
AdvaMed®, the Medtech Association, released the following statement from President and CEO Scott Whitaker and Zach Rothstein, Executive Director of AdvaMedDx®, on FDA’s recently proposed LDT rule.
The Dx Summit convenes leaders from the IVD and clinical diagnostic lab community to explore the most significant policies, technologies, and market shifts in the industry.
Today, AdvaMed®, the MedTech Association, released updated reports, in collaboration with Deloitte on frameworks for the comprehensive assessment of medical technologies and diagnostic tests. These seminal reports had been developed…
AdvaMed®, the Medtech Association, joined members the Global Medical Technology Alliance (GMTA) to welcome the recently released World Health Assembly (WHA) resolution on Strengthening Diagnostic Capacity.
This Women’s Health Month, AdvaMed® is highlighting new developments in breast cancer screening.
On March 29, AdvaMed® responded to the Senate HELP Committee’s request for information on policy priorities for the reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA).
Today, AdvaMed®, the medtech association, released the following statement from President and CEO Scott Whitaker on the introduction of the bipartisan Verifying Accurate, Leading-edge IVCT Development (VALID) Act. Introduced in…
Today, AdvaMed®, the medtech association, applauded the introduction in the House and Senate of the bipartisan Saving Access to Laboratory Services Act (SALSA) by Senators Sherrod Brown (D-OH) and Thom…